Avinger (AVGR) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Avinger (AVGR) Tops Q2 EPS by 7c
July 28, 2015 4:02 PM EDT
Achieved Positive 30-Day Results for Clinical Trial for Pantheris
Expanded Installed Base of Company's Lumivascular Platform
REDWOOD CITY, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported results for the second quarter ended June 30, 2015.
Recent Highlights
Surpassed primary efficacy endpoint performance goal in 30-day data from VISION Trial. Results demonstrated that...
More
July 28, 2015 4:02 PM EDT
Achieved Positive 30-Day Results for Clinical Trial for Pantheris
Expanded Installed Base of Company's Lumivascular Platform
REDWOOD CITY, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported results for the second quarter ended June 30, 2015.
Recent Highlights
Surpassed primary efficacy endpoint performance goal in 30-day data from VISION Trial. Results demonstrated that...
More
